Clinigen appoints Fernando Ballester as Chief Financial Officer

LONDON, UK, 2 July 2024 – Clinigen, the global pharmaceutical services company, today announces the appointment of Fernando Ballester as Chief Financial Officer (CFO), effective 1 August 2024. Fernando, who has a background in audit and financial planning and analysis, joins Clinigen with an impressive track record.

Fernando has held a number of CFO positions for both listed and Private Equity backed businesses in the pharmaceutical sector, most recently at ICE Pharma in Italy since 2019. In his two decades working at world leading companies in different countries, he has been responsible for local, regional and global finance operations ranging from $60M to $1B. His extensive experience includes M&A, business integration, restructuring programs, finance transformation, commercial and operational excellence programs and ERP implementation. 

Fernando’s deep financial acumen, strategic vision, and proven leadership skills will be instrumental as Clinigen continues to drive revenue growth and expand its service offering to pharmaceutical and biotech companies. Fernando is also a qualified accountant and holds an MBA from Sao Paolo Business School. 

Jerome Charton, CEO commented, “This appointment marks a new and exciting direction for Clinigen's financial leadership. Fernando's expertise will ensure we have the financial strength to achieve our ambitious goals. We are delighted to welcome him on board to collaborate on implementing our strategic vision.” 

Fernando Ballester, CFO commented, “I am thrilled to join Clinigen, a company I have long admired. My focus will be on driving financial excellence and supporting our strategic initiatives to ensure sustainable growth and value creation.” 

Fernando takes over from Emmanuel Walter who has been Clinigen’s interim CFO for the last six months. Emmanuel has provided invaluable leadership and guidance and has ensured a smooth transition, significantly contributing to improving Clinigen’s financial reporting and Board governance. 

Fernando’s appointment is another step to help Clinigen further advance into a world leading pharma services company, aiming to get essential medicines across the world to the patients that need them the most. 

About Clinigen  

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to accelerate access to medicines for patients in every corner of the globe. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries and provides access in more than 130 countries every year. 

For more information on Clinigen, please visit http://www.clinigengroup.com.